Trial Profile
A Study of Ipilimumab Plus Cytokine-induced Killer Immunotherapy for Stage II Melanoma Patients
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2015
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms Melanoma001
- 17 Jul 2015 New trial record